17.9Mpeople die from cardiovascular disease every year — the majority preventable
1.28Badults worldwide have high blood pressure, yet fewer than 1 in 5 have it under control
$1T+annual global economic burden of cardiovascular disease alone
Every year, 17.9 million people die from cardiovascular disease — the majority preventable. High blood pressure alone affects 1.28 billion adults worldwide, yet fewer than one in five have it under control. Most people who survive into retirement do not thrive — they spend their final decades managing chronic illness, navigating inadequate healthcare systems, and living in places that accelerate their decline rather than extend their health.
This is not inevitable. It is a knowledge problem.
Millions of people develop heart disease because they do not have the right information, at the right time, to make better decisions about how they live. People retire in places that shorten their lives because nobody has given them the intelligence to choose differently.
"Both issues are preventable. It's time for a change."
02 — The Landscape
Billions are being invested in longevity. But not for everyone.
The biological approach to longevity is extraordinary science. It is not, however, an inclusive solution.
The world's leading longevity companies are attacking ageing from a biological perspective. Epigenetic reprogramming. Gene therapy. Stem cell medicine. AI drug discovery. Companies backed by Jeff Bezos, Sam Altman, and Larry Ellison. Billions of dollars chasing the science of living longer. While the science is remarkable, the accessibility is not.
Altos Labs raised $3 billion to develop cellular rejuvenation therapies. Retro Bio, backed by OpenAI's Sam Altman, is developing programmes to reverse cellular ageing. NewLimit, co-founded by Coinbase's Brian Armstrong, is pioneering epigenetic reprogramming medicines.
$3Braised by Altos Labs alone to develop cellular rejuvenation therapies
Decadesuntil most biological longevity treatments reach clinical approval for general use
Fewof the 8 billion people on earth who will be able to access or afford these treatments
These treatments are expensive, experimental, and out of reach for most. The treatments being developed today could take decades to reach clinical approval, cost thousands per treatment, and serve a narrow demographic.
"Altos Labs is building a world where disease reversal is possible. We are building a world where healthy longevity is universally accessible."
We are tackling longevity from a different perspective — more scalable and more impactful. Not because biological approaches are wrong, but because they are not inclusive.
03 — Our Thesis
The two biggest longevity factors are not in a lab.
They are in your daily life. And they are available to everyone.
We believe the two most impactful controllable factors in how long and how well you age are not found in a laboratory. They are found in your daily life. How you live.Where you live.
How you live — your daily habits, what you eat, how you move, how you manage stress, how you sleep — determines the majority of your cardiovascular health and longevity. Research consistently shows that up to 80% of heart disease is preventable through lifestyle choices alone. The difference between decades of healthy life and decades of chronic illness.
80%of heart disease is preventable through lifestyle choices alone
5–15years of healthy life added by choosing the right place to retire
Where you live — your access to healthcare, the air quality of your environment, the walkability of your neighbourhood, the strength of your social connections, the financial sustainability of your location — adds or subtracts years from your life in ways most people never consider. Studies show that choosing the right place to retire can add 5 to 15 years of healthy life. Yet most people make this decision based on cost of living and proximity to family — never once considering the longevity implications of their choice.
"These two factors are available to everyone and can easily be actioned because they do not require a clinical trial or biohack, just knowledge."
Not everyone can change where they live. Everyone can change how they live. Our apps reflect this reality — one serves those with location mobility, one serves everyone. Together they make healthy longevity universally accessible. Because knowledge has value regardless of whether you can act on it today.
04 — Our Approach
Knowledge apps for longevity.
Daily companions that improve decisions and extend lives.
Knola builds knowledge apps — AI-powered applications that constantly transform your personal data into insights that help you make better decisions every day to extend your healthy years.
"Data informs. Knowledge transforms."
Knowledge apps go further. They analyse your data continuously, identify patterns invisible to the human eye, and surface personalised insights that tell you exactly what is adding years to your life — and what is taking them away. They transform information into action. Every day. Automatically.
And because knowledge apps are universally accessible — available on any smartphone, at a fraction of the cost of biological interventions — they create the possibility of a future where healthy longevity is not a privilege, but a reality for everyone.
Knowledge apps are AI-powered apps that constantly transform your data into longevity insights.
05 — Our Apps
Two knowledge apps. Two critical longevity factors.
Each app addresses one of the two biggest controllable factors in how long and how well you age.
Your Body — How You Live
Ovana
Build habits that extend your healthy years
Ovana is a knowledge app for heart health. It tracks your blood pressure, analyses your daily habits, and surfaces the personalised insights that help you build the behaviours that extend your healthy years. High blood pressure is the single largest risk factor for cardiovascular disease — the world's leading cause of death. Yet it is largely manageable through lifestyle. Ovana exists to close the gap between knowing your blood pressure is high and knowing exactly what to do about it.
RetireAway is a knowledge app for retirement location intelligence. It analyses your health profile, financial situation, and lifestyle preferences to identify the places in the world where you will live longest, thrive most, and spend least. Most people choose where to retire based on instinct, familiarity, or cost. RetireAway gives them the intelligence to choose based on what actually matters — their longevity.
Together, Ovana and RetireAway form the two pillars of Knola's longevity intelligence platform. Users who want a complete, integrated picture — combining their health, location, and financial data into a single personalised longevity plan — can connect both through Knola.
06 — Our Mission
We envision a future where healthy longevity is accessible to everyone.
Living healthier, longer should not be privilege but a reality for everyone.
Every year, millions die from high blood pressure and preventable illness. Most people spend their final decades sick, in places that accelerate their decline, without the information to have chosen differently. This should end.
We believe the longevity challenge is not only a biological one. It is a knowledge one. And knowledge, unlike gene therapy, can reach everyone. A farmer in Nigeria. A retiree in the Philippines. A working parent in Atlanta. Each of them has the capacity to add healthy years to their life by making better decisions about how and where they live. Knola exists to give them the knowledge to do exactly that.
"The world's longevity companies are building for the few. We are building for everyone."
Our mission: end preventable heart disease, promote healthy ageing, and transform how people retire..
07 — The Opportunity
The convergence of AI and longevity creates a unique window.
The right space. The right time. The right approach.
$600Bprojected global longevity market by 2025
$1T+annual cost of cardiovascular disease to the global economy
1.28Bpeople with high blood pressure — Knola's addressable market for Ovana alone
The global longevity market is one of the fastest growing sectors in the world. Cardiovascular disease costs the global economy over $1 trillion annually. The retirement services market is worth trillions more. Knola sits at the intersection of all three — health, longevity, and retirement — at the precise moment that AI makes personalised knowledge apps possible at scale.
AI has created a new category of product that did not exist five years ago — apps that learn from your data continuously, improve their recommendations over time, and deliver genuinely personalised intelligence at consumer price points. This is the infrastructure Knola is built on. And it is only becoming more powerful.
"The biological longevity companies will serve the few. Knola will serve everyone."
We are building two focused apps for two distinct high-value problems — hypertension management and retirement location intelligence. The biological longevity companies will serve the few. Knola will serve everyone. That is the opportunity. That is the company we are building.